Buradasınız

Anasayfa » Content

KRONİK HEMODİYALİZ PROGRAMINDAKİ ERKEK HASTALARDA BROMOKRİPTİN TEDAVİSİNİN GONADAL FONKSİYONLAR VE PROLAKTİN DÜZEYLERİNE ETKİSİ

EFFECT OF BROMOCRIPTINE THERAPY ON GONADAL FUNCTIONS AND PROLACTIN LEVELS IN MALE PATIENTS ON CHRONIC HEMODIALYSIS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Blood levels of FSH, LH, E2, T and PRL hormones were studied in 30 male patients with chronic renal failure (CRF) on chronic hemodialysis treatment. FSH, LH, Ei and PRL levels of these 30 male patients were statistically significantly higher (p<0.001) than the levels of the control group, where as the T levels were significantly lower (p<0.001). After intramuscu¬lar administration of 50 mg parlodel to these 30 male patients, hormone levels were measured on the 1st, 7th, 15th, 30th, 45th days of injection. There were no significant difference between the pre and post treat¬ment values of FSH, LH and E2 (p>0.05), but the dec¬rease in PRL level with in the first 15 days after the treatment was found to be statistically significant (p<0.001). Statistically significant elevation of T hor¬mone levels were also detected from the 7th day of treatment (p<0.01). Besides experiencing an increase in libido and sexual functions, most of the patients stated their satisfaction with their sexual activities. As a conclusion, we believe that treatment with bro-mocryptine is likely to be successful in the treatment of sexual dysfunction in male patients with CRF on chronic hemodialysis treatment
Bookmark/Search this post with
Abstract (Original Language): 
Kronik hemodiyaliz programında olan 30 erkek hastada FSH, LH, E2, T ve PRL hormon düzeylerine bakıldı. Bu değerler kontrol grubu olarak seçilen sağlıklı 10 erkeğin hormon düzeyleri ile karşılaştırıldı. Hemodiyalize giren erkek hastaların FSH, LH, E2 ve PRL değerleri kontrol grubunda saptanan değerler¬den anlamlı olarak yüksek (p<0.001), T değerleri ise anlamlı olarak düşük bulundu (p<0.01). Kronik böb¬rek yetmezlikti hemodiyalize giren 30 erkek hastaya daha sonra 50 mgparlodel i.m. yapıldı. Tedavi sonrası 1..7., 30. ve 45. gün hormon değerlerine bakıldı. Tedavi sonrası FSH, LH, E2 değerlen ile tedavi önce¬si FSH, LH, E2 değerleri arasında anlamlı bir fark bulunamazken (p>0.05), tedavi sonrası PRL değerle¬rinde ilk 15 gün içinde giderek anlamlı bir azalma gözlendi. 15. gün PRL değerlerindeki düşme istatis¬tiksel olarak anlamlı bulunmuştur (p<0.001). T hor¬monunda ise tedavi sonrası en fazla 7. günden itiba¬ren olmak üzere istatistiksel olarak anlamlı bir artış görüldü (p<0.01). Ayrıca hastaların büyük çoğunlu¬ğunda libido ve seksüel fonksiyonlarda artış gözlendi. Seksüel yönden kendilerini daha iyi hissettiklerini ifa¬de ettiler. Sonuç olarak hemodiyalize giren kronik böbrek yetmezlikti erkek hastalarda, bromokriptin te¬davisinin seksüel fonksiyon bozukluklarının tedavisin¬de yararlı olabileceğine inanıyoruz.
FULL TEXT (PDF): 
PDF icon pdf_tndt_88.pdf
  • 2
101-105
  • Turkish

REFERENCES

References: 

1. Stewart M, Horton R, Bentley D. Regulation of gonadal function in uremia. Metabolism 1974; 23:1065-1073.
2. Linsday RM, Briggs JD. Gynecomastia: An endocrino-logic complication of hemodialysis. Ann Intern Med
1968; 69:67-72.
3. Feldman HA, Singer I. Endocrinology and metabolism in uremia and dialysis, clinical review. Medicine 1974;
54: 345-350.
4. Distiller LA, Morley JE, Sagel J, Pokroy M, Rakbin R.
Pituitary-gonadal function in chronic renal failure. The effect of luteinizing hormone releasing hormon and the influence of dialysis. Metabolism 1975; 24: 711.
5. Mastroglacome I, Feghali V, Besi L, Serafini E. Prolac-tin, gonadotropins, testesteron and estrogens in uremic men undergoing periodic hemodialysis. Arch Androl
1982;4:279-282.
6. Chen JC, Vidt DC, Zorn EM. Pituitary-Leydig cell func¬tion in uremic males. J Clin End Metab 1970; 31: 14-17.
7. Bommer J. Management of uremic patients with sexual
difficulties. Cont Nephrol 1986; 50: 139-152.
8. Wass VJ, Muir JW, Wass JA. Uremic sex. N Engl Med
1977; 297: 726.
9. Ermolenko VM, Kukterich AV, et al. Parlodel treatment of uremic hipogonadism in men. Nephron 1986; 42: 19¬22.
10. Massry SG, Goldstein DA. Impotence in patients with uremia. Possible role of parathyroid hormon. Nephron 1977;19:305-310.
11. Blumberg A, Wildbolz A, Weidmann P. Influence of 1.2 dihydroxy cholecalciferol on sexual dysfunction and re¬lated endocrine parameters in patients on maintenance
hemodialysis. Clin Nephrol 1980; 13: 208-214.
12. Antoniou LD, Shalhoub RJ. Zinc in the treatment of im¬potence in chronic renal failure. Dial Transplant 1978;
7: 912-916.
13. Mahajan SK, Abbasi AA, Rabban P, et al. Effect of oral zinc therapy on gonadal function in hemodialysis pati¬ents. Ann Intern Med 1982; 97: 357-361.
14. Brode AC, Johnston DG, Ward MK. Absence of a thera-petic effect of zinc in the sexual dysfunction of hemodi-
alysis patients. Lancet 1980; 2: 618-619.
15. Sprenger K, Schmitz J. Zinc arid sexual dysfunction.
Contr Nephrol 1984; 38: 119-125.
16. Lim VS, Auletta F, Kathpalia S. Gonadal dysfunction in chronic renal failure an endocrinologic review. Dialysis
Transplant 1976; 7: 896-907.
17. Santen RJ, Leonard JM, Sherins RJ, Gandy HM. Short
and long term effects of clomiphene citrate on the pitui-
tary testicular axis. Clin Endocrinol Met 1971; 33: 970.
18. Cargille CM, Ross GT, Bandin. Clomiphene and gona-dotropin in men. Lancet 1968; 2: 1298.
19. Bardin CW, Ross GT, Lipsett MB. Site of action of clo-miphene citrate in men. Clin Endoc Met 1967'; 27: 1558.
20. Hamilton CR, Henken RI, Gordon W, Kliman B. Alfac-
tory status and response to clomiphene in male gonadot-rophine deficiency. Ann Intern Med 1973; 78: 47.
21. Procci WR, Goldstein DA. Sexual dysfunction in the male patient with uremia. Kidney In: 1981; 19: 317-323.
22. Susan HH, Susan G, Mark EM. Hyperprolactinemia in patients with renal insufficiency and chronic renal failu¬re. Requiring hemodialysis or chronic ambulatory peri¬toneal dialysis. Am J Kidney Dis 1986; 6 (4): 245-249.
23. Gomez F, Wanters JP. Endocrine abnormalities in pati¬ents undergoing long term hemodialysis, the role of pro-
lactin. Am J Med 1980; 68: 522-530.
24. Carloström K, Pousette A, Stege R, Lindholm A. Serum hormon levels in men with end stage renal disease. Scan
Urol Nephrol 1990; 24: 75-78.
25. Bommer J, Ritz E, Pozo E, Bommer G. Improved sexual function in male hemodialysis patients on bromocripti-ne. Lancet 1979; 2: 496A97.
26. Ramirez G, Butcher DE, Newton JL, et al. Bromocripti-ne and the hypophyseal function in patients with chronic hemodialysis. Am Kid Dis 1985; 6: 111-118.
27. Thorner MO. Prolactin. Clin End Metab 1977; 6: 201¬202.
28. Marcovitz S, Ferieseh H. Regulation of prolactin secre¬tion in man. Clin Res 1971; 19: 773.
29. Milutinovic S, Orsonic D. Hyperprolactinemia in urea-mi. Abstract of XXII and Congress of the EDTA. Brus-
sel 1985; 25: 29.
30. Franks S, Jacob H. Hyperprolactinemia and impotence.
Clin Endocr 1978; 8: 227.
31. Muir JW, Besser GM, Edwards CRW, Rees LH, Cafell WR, et al. Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis.
Clin Nephrol 1983; 20: 308-314.
32. Stefanovic V, Bogicevic M, Köstis S. Gonadal function in male patients on maintenance hemodialysis. EDTA
1985; 13: 25-29.
33. Franchimont P, Millet D, Letawe J, Nettler A. Relati¬onship between spermatogenesis and serum gonadotrop-hin levels in azopermis and oligospermia. Clin Endocri-
nol Met 1972; 34: 1003.
34. Tharad L, Graben N, Plewa G, Siegel R. Effects of pro-lactin suppression on hypogonadism in patients on ma¬intenance hemodialysis. Proc EDTA 1980; 17: 323-327.
35. Victoria L, Fang V. Gonadal dysfunction in uremic
men. Am J Med 1975; 58: 655-662.

Thank you for copying data from http://www.arastirmax.com